풀크럼 테라퓨틱스(FULC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.76 (-0.27%), 시가총액 $0.49B, 52주 최저~최고 $5.07 ~ $14.60.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use pate
풀크럼 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
풀크럼 테라퓨틱스의 현재 주가는 $3.76 (-0.27%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
풀크럼 테라퓨틱스의 시가총액은 약 $0.49B입니다.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical n